BREAKING: Chris Wallace just completely demolished Donald Trump’s debate performance. Wallace went so far as to call Donald Trump’s debate performance tonight the worst debate performance in American history. Retweet to make sure all Americans see this.

Wharton professor here! Here are the Penn Wharton Budget Model estimates: — Harris’ proposal increases the deficit by $1.2 trillion, with low- and middle income households benefiting disproportionately. — Trump’s proposal increases the deficit by $5.8 trillion. Details below 👇

BOOM! Childless Cat Lady Taylor Swift endorses Kamala Harris.

BREAKING: Taylor Swift just endorsed Kamala Harris for President.

Like it or not: Germany’s energy system is fully operational, with more than 50% renewables. And we are shutting down – not building – coal & nuclear plants. Coal will be off the grid by 2038 at the latest. PS: We also don’t eat cats and dogs. #Debate2024

"In Springfield they're eating the dogs." 😂😂🤣🤣

PANDAS PRODIGE 44 BR-PDAC ➡️mFFX vs mFFX + caperads 50.4Gy ➡️No diff in R0 resection rate ➡️No diff in mOS 32.8 vs 30mths ➡️numerically longer locoregional recurrence rate in RT arm but not sig ‼️imp to note in those randomised how many get to adjuvant ~50% #ESMO2024 HPB Dublin

How to Debate youtu.be/MXmi5ea2hIY

The one and only Sarah Cooper is back!🤣

Another Low Dose IO trial from India 🇮🇳 CMC Vellore 🙂👍 Necesity is mother of all inventions. Our patients can not afford full dose IO so we have to modify the dose and it works 🙂👍

He's making Germany laugh again. Not an easy feat. #TrumpIsALaughingStock

🔥of the press Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial Nature Medicine 👇doi.org/10.1038/s41591… ESMO - Eur. Oncology #ESMOAmbassadors #ESMO24

#ESMO24 ESMO - Eur. Oncology Excellent discussion by Jenny Seligmann contextualizing IO in early stage #CRCsm NICHE-2 and NICHE-3 Myriam Chalabi & IMHOTEP 📌non-randomized datasets, robust and meaningful efficacy 📌higher pCR with more IO ✅is this data enough to change practice? YES ⛔️is

I do not think that a randomized trial comparing Neoadj IO in early stage colon cancer compared with adj chemotherapy is feasible anymore - and likely not even ethical #ESMO2024

Nothing is 100% in life except the 3yr DFS of NICHE-2 study!@Amitmahipal79 Myriam Chalabi antony ruggeri Dr Joseph McCollom DO Ibrahim Halil SAHIN, MD Anup Kasi MD MPH Suneel Kamath MD Bassam Estfan

Sharlene Gill, MD, MPH, MBA, FASCO ESMO - Eur. Oncology Kimmie Ng, MD, MPH Alliance for Clinical Trials in Oncology OncoAlert OncologyEducation Median PFS wasn’t significant in phase II either

#TrumpIsALaughingStock

Elon Musk = Paul Darros? Only nerds will understand… #orphanblack

Obama announcing the death of bin Laden vs. Trump announcing the death of al-Baghdadi will forever be one of the funniest videos on the internet.

some thoughts… #ESMO2024 - the DFS data of NICHE2 are definitive! Neoadj / definitive IO should be SOC in dMMR CRC. Re ATOMIC… Hard to compete with 100% 3yr DFS. And… Where are the ATOMIC data? Way overdue! Frank Sinicrope, MD Myriam Chalabi OncoAlert